SGLT2抑制剂与2型糖尿病患者新发特应性皮炎风险降低相关:全国性活性对照队列研究
该研究利用台湾全民健康保险数据库,纳入148354例SGLT2i使用者和322703例DPP4i使用者,比较新发特应性皮炎(AD)风险。经IPTW调整后,SGLT2i组AD风险显著低于DPP4i组(HR 0.847),最高剂量SGLT2i与最低AD风险相关(HR 0.647),男性获益更明显(HR 0.750)。
要点
- 与DPP4i相比,SGLT2i使用者的AD发生率更低(9.742 vs 12.070/1000 PY)。
- IPTW调整后SGLT2i组AD风险显著降低(HR 0.847),不同SGLT2i类型效果一致。
- 最高剂量SGLT2i与最低AD风险相关(IPTW调整HR 0.647),男性HR 0.750。
核心结论
- 在糖尿病患者中,与DPP4i相比,SGLT2i对AD具有显著保护作用,且存在剂量反应关系。
研究设计与样本
- 全国性活性对照队列研究,使用台湾全民健康保险数据库,纳入2016年5月至2018年12月新启用SGLT2i或DPP4i的2型糖尿病成人。
- SGLT2i组148354例,DPP4i活性对照组322703例,采用IPTW平衡基线特征,Cox比例风险模型估计HR及95%CI。
主要发现
- SGLT2i使用者AD发生率低于DPP4i使用者(9.742 vs 12.070/1000 PY)。
- IPTW调整后SGLT2i组AD风险显著低于DPP4i组(HR 0.847)。
- 不同SGLT2i类型均显示一致的AD保护效应。
- 最高剂量SGLT2i与最低AD风险相关(IPTW调整HR 0.647),敏感性分析一致。
- 男性SGLT2i使用者AD风险低于女性(IPTW调整HR 0.750)。
临床怎么用
- 对于2型糖尿病患者,选用SGLT2i可能同时降低新发AD风险,尤其在高剂量和男性患者中保护效应更明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel class of antidiabetic medication, have emerged as a key treatment option in diabetes management. Notably, SGLT2i promote glucose and sodium excretion through urine, a mechanism that may be implicated in the potential association between SGLT2i use and risk of atopic dermatitis (AD). OBJECTIVES: To investigate the relationship between SGLT2i use and new-onset AD in people with diabetes. METHODS: This nationwide active-comparator cohort study used data from the Taiwan National Health Insurance database to investigate the association between SGLT2i use and AD risk. The study included adults with type 2 diabetes mellitus who initiated SGLT2i or DPP4i between May 2016 and December 2018, with no prescriptions for other SGLT2i or DPP4i in the 12 months prior to cohort entry. A total of 148 354 SGLT2i users were identified as the study group, while 322 703 DPP4i users were designated as the active comparator group. The primary outcome was the incidence of AD. To minimize potential confounding, inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics, medical history and ever having used medication between the two groups. Additionally, sensitivity analyses, subgroup analyses and sex-specific assessments were conducted to further validate the findings. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of developing AD. RESULTS: SGLT2i users had a lower incidence of AD (9.742 vs. 12.070 per 1000 PY) than DPP4i users. SGLT2i users had a significantly lower risk of AD compared with DPP4i users (HR 0.847) after IPTW adjustment. Different types of SGLT2i also showed a consistent protective effect for AD. Notably, the highest SGLT2i dosage was associated with the lowest risk of AD (IPTW-adjusted HR 0.647), consistent across sensitivity analyses. Additionally, men who use SGLT2i exhibited a much lower risk of AD (IPTW-adjusted HR 0.750) than women who use SGLT2i. CONCLUSIONS: SGLT2i show a significant protective effect against AD in patients with diabetes compared with DPP4i. This robust finding, consistent across weighting and sensitivity analyses, supports SGLT2i use, with a strong protective effect also found in the dose-response analysis. Atopic dermatitis (‘AD’ for short) is a common skin disease that causes skin to feel itchy and inflamed. AD affects millions of people worldwide. Our study, which was done in Taiwan, wanted to find out if a type of diabetes medication called ‘SGLT2 inhibitors’ can help prevent AD in people with diabetes. We used information from the Taiwan National Health Insurance database. We included information from 148,354 patients with diabetes who used SGLT2 inhibitors and compared them to 322,703 patients who used another type of treatment called ‘DPP4 inhibitors’. We wanted to see if patients with diabetes who used SGLT2 inhibitors had less chance of developing AD than people who took DPP4 inhibitors. Specific statistical tests were used to ensure a fair comparison between the two groups. Other statistical tests were done to confirm the findings. The results suggest that people with diabetes who use SGLT2 inhibitors have a much lower risk of developing AD than those who take DPP4 inhibitors. We also found that people who took higher doses of SGLT2 inhibitors were at much less risk of developing AD. The results were consistent for the different types of SGLT2 inhibitor taken by patients. Another important finding was that men with diabetes who took SGLT2 inhibitors had a lower risk of AD than women. Our findings suggest that SGLT2 inhibitors might help manage diabetes and have other benefits like reducing the risk of a person developing AD.
引用
- Wen YL, Hsu WT, Chen YH, et al. Sodium-glucose cotransporter 2 inhibitors and inverse risk of new-onset atopic dermatitis in a cohort with diabetes: a nationwide active-comparator study. Br J Dermatol. 2025. PMID: 40037684. doi:10.1093/bjd/ljaf086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。